



Astec LifeSciences Ltd.

Date: 30th June, 2025

To,

| | |
|---|---|
| The Manager Listing Department BSE Limited P. J. Towers, Dalal Street, Fort Mumbai – 400 001 Ref.: BSE Scrip Code No. “533138” | The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra - Kurla Complex Bandra (East), Mumbai – 400 051 Ref.: “ASTEC” |
|---|---|

Sub.: Regulations 30 and 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”) and Outcome of the Meeting of the Board of Directors of Astec LifeSciences Limited (the “Company”) held on 30th June, 2025

Dear Sir / Madam,

This is in furtherance to the Meeting of the Board of Directors of the Company (the “**Board**”) held on 24th June, 2025, approving the offer and issuance of Equity Shares of the Company (the “**Rights Equity Shares**”) for an amount not exceeding Rs. 250 Crore (Rupees Two Hundred and Fifty Crore), by way of a Rights Issue (the “**Rights Issue**”), in accordance with the Companies Act, 2013, as amended and the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, other applicable laws and in furtherance to our prior intimation dated 24th June, 2025 of Meeting of the Board of Directors to be held on 30th June, 2025.

Pursuant to the above referred, we wish to inform you that the Board of Directors, at its Meeting held today, i.e. on 30th June, 2025, has, *inter alia*, considered and approved the following terms of the Rights Issue:

- Total number of Rights Equity Shares and Rights Issue size:** 28,01,673 (Twenty-Eight Lakh One Thousand Six Hundred and Seventy-Three) Rights Equity Shares each on a fully paid-up basis for an amount aggregating to Rs. 249.35 Crore (Rupees Two Hundred and Forty-Nine Crore and Thirty-Five Lakh Only) (assuming full subscription and payment of call monies).
- Rights Issue Price:** Rs.890/- (Rupees Eight Hundred and Ninety Only) per Rights Equity Share [including a premium of Rs.880/- (Rupees Eight Hundred and Eighty Only) per Rights Equity Share] to be fully paid at the time of application in the Rights Issue.
- Record date:** Friday, 4th July, 2025 for determining the shareholders who will be eligible to receive the Rights Entitlement.
- Rights Issue period:**
 - Rights Issue Opening Date: Monday, 14th July, 2025;
 - Last date for on-market renunciation: Tuesday, 22nd July, 2025;
 - Last date for off-market: Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat accounts of the Renouncees on or prior to the Rights Issue Closing Date; and



Regd. Office :
“Godrej One”, 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai - 400079,
Maharashtra, India
Telephone No. : 022-25188010
Fax No. : 022-22618289
Email id : astecinfo@godrejastec.com
Website : www.godrejastec.com
CIN : L99999MH1994PLC076236

4. Rights Issue Closing Date: Monday, 28th July, 2025*

**The Board or the Rights Issue Committee will have the right to extend the Rights Issue period as it may determine from time to time but not exceeding 30 days from the Rights Issue Opening Date (inclusive of the Rights Issue Opening Date).*

e. **Outstanding Equity Shares:**

- prior to the Rights Issue: 1,96,11,710 (One Crore Ninety-Six Lakh Eleven Thousand Seven Hundred and Ten) fully paid-up Equity Shares of Face Value of Rs.10/- (Rupees Ten Only) each of the Company;
- post Rights Issue #: 2,24,13,383 (Two Crore Twenty-Four Lakh Thirteen Thousand Three Hundred and Eighty-Three) fully paid-up Equity Shares of Face Value of Rs.10/- (Rupees Ten Only) each of the Company.

Assuming full subscription and payment of call monies.

- Rights entitlement ratio:** The Rights Equity Shares are being offered on a rights basis to Eligible Equity Shareholders in the ratio of **1 (One) Rights Equity Share for every 7 (Seven) fully paid-up Equity Shares** held on the Record Date i.e., 4th July, 2025.

Concept of Rights Entitlement: The shareholders holding equity shares of the Company as on the Record date (the “**Eligible Equity Shareholders**”) will be entitled to Rights Entitlement (the “**REs**”). The REs shall be credited prior to the issue opening date, in the respective Demat account of the Eligible Equity Shareholders (the “**RE Holders**”) under the ISIN: INE563J20010. The Company has made necessary arrangements with NSDL and CDSL for credit of REs in the respective demat account of the eligible equity shareholders. RE holders can apply for Rights Issue or renounce the REs in full or in part. The Renunciation can be done using the secondary market platform of the Stock Exchanges (the “**On Market Renunciation**”) or through an off-market transfer (the “**Off Market Renunciation**”) within the timelines mentioned in the table above. To receive allotment of Rights Equity Shares, RE holders (who have received REs into their demat account or have purchased REs renounced by other RE holders) are required to make application for the Rights Issue on or before the Rights Issue Closing date by paying the full application amount. If no application for Rights Issue is made by the RE holders on or before the Rights Issue Closing Date, such REs shall lapse and no Rights Equity Shares for such lapsed REs will be allotted to them. For more details and terms, please refer to the Letter of Offer and Frequently Answered Questions when available on the website of the Company.

- ISIN for Rights Entitlement:** INE563J20010

- Other terms of the Rights Issue (including fractional entitlements):** To be included in the Letter of Offer to be filed by the Company.

The Meeting of the Board of Directors commenced at 4.15 p.m. and concluded at 4.43 p.m.

This intimation is issued in terms of Regulation 30 and 42 of the SEBI Listing Regulations.

We request you to please take the above information on your records and to disseminate it.



ASTEC

Astec LifeSciences Ltd.

The copy of the same is also being made available on the website of the Company i.e., <https://www.godrejastec.com/>.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

Tejashree Pradhan
Company Secretary & Compliance Officer
(FCS 7167)



Regd. Office :
"Godrej One", 3rd Floor,
Pirojshanagar, Eastern Express Highway,
Vikhroli (East), Mumbai - 400079,
Maharashtra, India
Telephone No. : 022-25188010
Fax No. : 022-22618289
Email id : astecinfo@godrejastec.com
Website : www.godrejastec.com
CIN : L99999MH1994PLC076236